UFT monotherapy as adjuvant chemotherapy for HER2 negative breast cancer patients who did not achieve pathologic complete response (non-pCR) after neoadjuvant chemotherapy: Phase 2 study.

Trial Profile

UFT monotherapy as adjuvant chemotherapy for HER2 negative breast cancer patients who did not achieve pathologic complete response (non-pCR) after neoadjuvant chemotherapy: Phase 2 study.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2014

At a glance

  • Drugs Tegafur/uracil (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Jan 2014 According to University Hospital Medical Information Network - Japan record, status changed from recruiting to discontinued.
    • 10 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top